# Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial

> **NCT01799486** · PHASE4 · UNKNOWN · sponsor: **Lin Bingliang** · enrollment: 300 (estimated)

## Conditions studied

- HBV-related Liver Cirrhosis

## Interventions

- **DRUG:** Telbivudine
- **DRUG:** Enecavir
- **DRUG:** Adefovir

## Key facts

- **NCT ID:** NCT01799486
- **Lead sponsor:** Lin Bingliang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-02
- **Primary completion:** 2013-02
- **Final completion:** 2015-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2013-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01799486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01799486, "Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01799486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*